No safety concerns yet in trials of GSK's Ebola vaccine

Almost 200 people have received GlaxoSmithKline's experimental Ebola vaccine in trials in the United States, Britain, Mali and Switzerland, and the safety data so far are "very satisfactory", scientists said on Monday.

The trials, which began just over two months ago, have been using healthy volunteers, rather than patients with Ebola, to test whether the vaccine is safe for humans.